93 related articles for article (PubMed ID: 2417650)
21. Prostatic recurrences in the management of superficial bladder tumors.
Lockhart JL; Chaikin L; Bondhus MJ; Politano VA
J Urol; 1983 Aug; 130(2):256-7. PubMed ID: 6410083
[TBL] [Abstract][Full Text] [Related]
22. [Blood and tissue levels of mitomycin C after intravesical instillation].
Flüchter SH; Hlobil H; Harzmann R; Rothe KF; Bichler KH
Urol Int; 1983; 38(6):321-8. PubMed ID: 6419427
[TBL] [Abstract][Full Text] [Related]
23. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Giesbers AA; Van Helsdingen PJ; Kramer AE
Br J Urol; 1989 Feb; 63(2):176-9. PubMed ID: 2495144
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
Järvinen R; Kaasinen E; Rintala E; Group TF
Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
[TBL] [Abstract][Full Text] [Related]
25. Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
Gözen AS; Umari P; Scheitlin W; Su FE; Akin Y; Rassweiler J
Arch Ital Urol Androl; 2017 Jun; 89(2):102-105. PubMed ID: 28679178
[TBL] [Abstract][Full Text] [Related]
26. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
[TBL] [Abstract][Full Text] [Related]
27. Ablative Intravesical Chemotherapy for Small Recurrent Non-Muscle-Invasive Bladder Cancer: A Prospective Study.
Decaestecker K; Lumen N; Ringoir A; Oosterlinck W
Urol Int; 2016; 96(1):14-9. PubMed ID: 25791565
[TBL] [Abstract][Full Text] [Related]
28. An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups.
Bosschieter J; Nieuwenhuijzen JA; Vis AN; van Ginkel T; Lissenberg-Witte BI; Beckers GMA; van Moorselaar RJA
Urol Oncol; 2018 Sep; 36(9):400.e7-400.e14. PubMed ID: 30064935
[TBL] [Abstract][Full Text] [Related]
29. [Stage P-1 primary neoplasia of the bladder. Critical evaluation of results obtained with the use of adriamycin and mitomycin C in the prevention of recurrences].
Liberti M; Tenaglia R; De Berardinis E; Gentile V
Minerva Med; 1984 Feb; 75(8):391-4. PubMed ID: 6424059
[TBL] [Abstract][Full Text] [Related]
30. Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.
Minervini R; Felipetto R; Viganò L; Pampaloni S; Fiorentini L
Urol Int; 1996; 56(4):234-7. PubMed ID: 8776821
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
Cho IC; Kim EK; Joung JY; Seo HK; Chung J; Park WS; Lee KH
Anticancer Res; 2012 Apr; 32(4):1493-8. PubMed ID: 22493392
[TBL] [Abstract][Full Text] [Related]
32. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
[TBL] [Abstract][Full Text] [Related]
34. Postoperative prophylactic intravesical instillation of cytosine arabinoside and mitomycin C in superficial bladder tumor. A follow-up study.
Omoto T; Kano M; Ariyoshi A; Momose S; Masaki Z; Morita I; Ishisawa N
Urology; 1982 Nov; 20(5):510-4. PubMed ID: 6815854
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
[TBL] [Abstract][Full Text] [Related]
36. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
[TBL] [Abstract][Full Text] [Related]
37. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
Milla P; Fiorito C; Soria F; Arpicco S; Cattel L; Gontero P
Cancer Chemother Pharmacol; 2014 Mar; 73(3):503-9. PubMed ID: 24442034
[TBL] [Abstract][Full Text] [Related]
38. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
39. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
40. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
